STAT Plus: The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results
Did Acadia's critics fail to appreciate the cleverness of designing a clinical trial for a mediocre medicine that could still deliver positive results?
.png)
No hay comentarios:
Publicar un comentario